Replies to post #171095 on Biotech Values

[jq1234]

ENTA doesn't own the full combo, just part of combo. That's where $25k assumption came from.

[DewDiligence]

ENTA—I must say I don't really understand where you come up with the $25K estimate for ABBV/ENTA all-oral combo. Olysio is priced at $66K for peg/riba combo and Sovaldi at [$84K]. There's no reason to believe that any all-oral combo will be priced at a discount to a peg/riba regimen.

My model’s $30K figure was a blended average of the US and EU. All of the prices you cited are for the US market only.

(I was in error earlier when I said the model's average price was $25K.)